<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>68(5)</volume><submitter>Sharma P</submitter><pubmed_abstract>A dire need exists for novel drugs to treat &lt;i>Mycobacterium tuberculosis&lt;/i> infection. In an effort to build on our early efforts targeting the MenG enzyme within the menaquinone biosynthetic pathway, we have pursued the optimization of diaryl amide JSF-2911 to address its poor metabolic stability and modest &lt;i>in vitro&lt;/i> potency. A hit evolution campaign focused on modification of the amine substructure within this hit compound, resulting in a range of analogues that have been profiled extensively. Among these derivatives, JSF-4536 and JSF-4898 demonstrated significantly improved biological profiles, notably offering submicromolar MIC values versus &lt;i>M. tuberculosis&lt;/i> and promising values characterizing the mouse liver microsome stability, aqueous solubility, and mouse pharmacokine</pubmed_abstract><journal>Journal of medicinal chemistry</journal><pagination>5774-5803</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12333353</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evolution of Small Molecule Inhibitors of &amp;lt;i&amp;gt;Mycobacterium tuberculosis&amp;lt;/i&amp;gt; Menaquinone Biosynthesis.</pubmed_title><pmcid>PMC12333353</pmcid><pubmed_authors>Sukheja P</pubmed_authors><pubmed_authors>Cangialosi J</pubmed_authors><pubmed_authors>Johnson K</pubmed_authors><pubmed_authors>Sharma P</pubmed_authors><pubmed_authors>Ocke E</pubmed_authors><pubmed_authors>Jiang Q</pubmed_authors><pubmed_authors>Li SG</pubmed_authors><pubmed_authors>Zimmerman MD</pubmed_authors><pubmed_authors>Tsotetsi K</pubmed_authors><pubmed_authors>Kumar P</pubmed_authors><pubmed_authors>Park S</pubmed_authors><pubmed_authors>Russo R</pubmed_authors><pubmed_authors>Nelson AM</pubmed_authors><pubmed_authors>Penalva-Lopez S</pubmed_authors><pubmed_authors>Suryavanshi S</pubmed_authors><pubmed_authors>Morrison E</pubmed_authors><pubmed_authors>Singh P</pubmed_authors><pubmed_authors>Sharma V</pubmed_authors><pubmed_authors>Alland D</pubmed_authors><pubmed_authors>Thadkapally S</pubmed_authors><pubmed_authors>Sarathy JP</pubmed_authors><pubmed_authors>Freundlich JS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evolution of Small Molecule Inhibitors of &amp;lt;i&amp;gt;Mycobacterium tuberculosis&amp;lt;/i&amp;gt; Menaquinone Biosynthesis.</name><description>A dire need exists for novel drugs to treat &lt;i>Mycobacterium tuberculosis&lt;/i> infection. In an effort to build on our early efforts targeting the MenG enzyme within the menaquinone biosynthetic pathway, we have pursued the optimization of diaryl amide JSF-2911 to address its poor metabolic stability and modest &lt;i>in vitro&lt;/i> potency. A hit evolution campaign focused on modification of the amine substructure within this hit compound, resulting in a range of analogues that have been profiled extensively. Among these derivatives, JSF-4536 and JSF-4898 demonstrated significantly improved biological profiles, notably offering submicromolar MIC values versus &lt;i>M. tuberculosis&lt;/i> and promising values characterizing the mouse liver microsome stability, aqueous solubility, and mouse pharmacokine</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-05-01T08:39:20.141Z</modification><creation>2026-04-19T03:07:59.362Z</creation></dates><accession>S-EPMC12333353</accession><cross_references><pubmed>40035499</pubmed><doi>10.1021/acs.jmedchem.4c03156</doi></cross_references></HashMap>